𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinico–pathological characteristics of BRCA1- and BRCA2-related breast cancer

✍ Scribed by Pierre O. Chappuis; Victoria Nethercot; William D. Foulkes

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
56 KB
Volume
18
Category
Article
ISSN
8756-0437

No coin nor oath required. For personal study only.

✦ Synopsis

Approximately 2% to 5% of all breast cancers are hereditary, meaning that the cancer predisposition is carried as a monogenic trait. Several highly penetrant breast cancer predisposing genes have been identified. These discoveries will permit a refined description of breast cancer occurring as part of the different genetic syndromes. We reviewed the medical literature on the clinico-pathological features of breast cancer associated with the major breast cancer susceptibility genes BRCA1 and BRCA2. BRCA1-associated breast cancers are more frequently ductal invasive, high-grade carcinomas with an important lymphocytic infiltration. They are aneuploid, estrogen and progesterone receptors negative, and p53 positive. BRCA2related breast cancers tend to be higher-grade tumors than are non-hereditary cases, although this association is less strong then for BRCA1 cases. These tumors exhibit substantially less tubule formation, but mitotic count and cellular pleomorphism do not differ significantly from those of sporadic cases. The overall pattern of the identified pathological characteristics suggests a carcinogenic pathway in BRCA1-and BRCA2-related breast cancers different from that found in sporadic cases. The probability of finding a BRCA1/2 germ-line mutation is partly determined by these characteristics. In addition, these features will likely influence the behavior of BRCA1/2-related breast cancer.

📜 SIMILAR VOLUMES

BRCA1-related breast cancer in Austrian
BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics
✍ Teresa M. U. Wagner; Regine A. Möslinger; Daniela Muhr; Gudrun Langbauer; Kora H 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 76 KB 👁 2 views

We identified 17 BRCA1 mutations in 86 Austrian breast and ovarian cancer families (20%) that were screened for mutations by denaturing high-performance liquid chromatography (DHPLC) and the protein truncation test (PTT). Eleven distinct mutations were detected, 4 of them (962del4, 2795del4, 3135del

Clinical management of BRCA1- and BRCA2-
Clinical management of BRCA1- and BRCA2-associated breast cancer
✍ Stephen E. Karp 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

The recent discovery of the breast cancer-associated genes BRCA1 and BRCA2 has changed the clinical care provided to women at high risk of breast cancer. We will review what is currently known about the clinical management of patients who bear (or are suspected of bearing) mutations in either of the

Prevalence of founder BRCA1 and BRCA2 mu
Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in hungary
✍ Marco Van der Looij; Csilla Szabo; Istvan Besznyak; Gyorgy Liszka; Bela Csokay; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 55 KB 👁 2 views

We have investigated the impact of BRACA1 and BRACA2 mutations that were frequently identified among Hungarian high-risk breast-ovarian cancer families (Ramus et al., 1997b, AJHG), on the development of breast and ovarian cancer in the general Hungarian population. The prevalence of 3 BRCA1 mutation